Oncolytics Biotech (TSE:ONC) has released an update.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Oncolytics Biotech reported positive results for its pelareorep and paclitaxel combination, showing significant improvements in survival rates for metastatic breast cancer patients. The company, with a solid cash position, plans to advance to a registration-enabling study. Oncolytics’ financial stability and promising clinical data suggest potential growth in the oncology sector.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.